DA Davidson Downgrades Medifast to Underperform, Lowers Price Target to $17.5
Benzinga Newsdesk 2 years ago
NewsDowngradesPrice TargetAnalyst Ratings
DA Davidson analyst Linda Bolton Weiser downgrades Medifast (NYSE:MED) from Neutral to Underperform and lowers the price target from $25 to $17.5.
DA Davidson analyst Linda Bolton Weiser downgrades Medifast (NYSE:MED) from Neutral to Underperform and lowers the price target from $25 to $17.5.